The DOI matches its Crossref record; 326 of the 326 references it cites were found in a registry or an index.
von Hippel-Lindau Disease
Abstract
von Hippel-Lindau disease, which is characterized by an increased risk of hemangioblastomas, clear cell renal carcinomas, and pheochromocytomas, is caused by inactivating mutations of the VHL tumor suppressor gene. The VHL gene product, pVHL, has multiple functions, but the best documented, and the one most clearly linked to tumor development, relates to its role as the substrate recognition module of a ubiquitin ligase complex that targets hypoxia-inducible factor (HIF) for destruction. pVHL function is often compromised in sporadic kidney cancers, and inhibitors of the HIF-responsive growth factor (vascular endothelial growth factor) are active against this disease. pVHL, by inhibiting atypical protein kinase C and hence JunB, also affects neuronal survival, as do the products of the other genes linked to familial pheochromocytoma or paraganglioma (NF1, RET, SDHB, SDHC, and SDHD). It is hypothesized that tumor-associated alleles of these genes allow primitive sympathoadrenal precursors to escape developmental culling, and that such cells are at increased risk of forming tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–326 of 326
Zatyka, M., da Silva, N. F., Clifford, S. C., Morris, M. R., Wiesener, M. S., Eckardt, K., Houlston, R. S., Richards, F. M., Latif, F., & Maher, E. R. (2002) · PubMed · doi:10.25405/ncl.34582002 · Cited by 147
The RNA polymerase II general elongation factors
Reines, D., Conaway, J. W., & Conaway, R. (1996) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(96)10045-1 · Cited by 147
Lee, J., Dong, S. M., Park, W. S., Yoo, N. J., Kim, C. S., Jang, J., Chi, J. G., Zbar, B., Lubensky, I. A., Linehan, W. M., et al. (1998) · PubMed · Cited by 146
VHL Gene Deletion and Enhanced VEGF Gene Expression Detected in the Stromal Cells of Retinal Angioma
Chan, C. C. (1999) · Archives of Ophthalmology · doi:10.1001/archopht.117.5.625 · Cited by 146
Characterization and comparative analysis of the EGLN gene family
Taylor, M. S. (2001) · Gene · doi:10.1016/s0378-1119(01)00633-3 · Cited by 145
Pal, S., Claffey, K. P., Dvorak, H. F., & Mukhopadhyay, D. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.44.27509 · Cited by 144
Software and database for the analysis of mutations in the VHL gene
Béroud, C. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.1.256 · Cited by 143
Michel, J. J. C., & Xiong, Y. (1998) · PubMed · Cited by 141
Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products
Schoenfeld, A. R., Davidowitz, E. J., & Burk, R. D. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.15.8507 · Cited by 140
Lee, C., Kim, S. J., Jeong, D. G., Lee, S. M., & Ryu, S. E. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210385200 · Cited by 138
Blankenship, C., Naglich, J. G., Whaley, J. M., Seizinger, B. R., & Kley, N. (1999) · Oncogene · doi:10.1038/sj.onc.1202473 · Cited by 138
Kurban, G., Hudon, V., Duplan, E., Ohh, M., & Pause, A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2560 · Cited by 135
A polymeric form of fibronectin has antimetastatic effects against multiple tumor types
Pasqualini, R., Bourdoulous, S., Koivunen, E., Woods, V. L., & Ruoslahti, E. (1996) · Nature Medicine · doi:10.1038/nm1196-1197 · Cited by 132
Nwogu, J. I., Geenen, D., Bean, M., Brenner, M. C., Huang, X., & Buttrick, P. M. (2001) · Circulation · doi:10.1161/hc4301.097193 · Cited by 131
RNA polymerase II transcription factor SIII. I. Identification, purification, and properties.
Bradsher, J., Jackson, K. W., Conaway, R. C., & Conaway, J. W. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)74431-7 · Cited by 130
Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma
Gnarra, J. R., Duan, D. R., Weng, Y., Humphrey, J. S., Chen, D. Y. T., Lee, S. B., Pause, A., Dudley, C. F., Latif, F., Kuzmin, I., et al. (1996) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(95)00012-5 · Cited by 130
Silva, J. D., Lacombe, C., Bruneval, P., Casadevall, N., Leporrier, M., Camilleri, J.-P., Bariety, J., Tambourin, P. E., & Varet, B. R. (1990) · Blood · doi:10.1182/blood.v75.3.577.577 · Cited by 129
Linehan, W. M., & Zbar, B. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.006 · Cited by 129
Li, Z., Wang, D., Na, X., Schoen, S. R., Messing, E. M., & Wu, G. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00534-x · Cited by 128
VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells.
Bindra, R. S., Vasselli, J. R., Stearman, R. S., Linehan, W. M., & Klausner, R. D. (2002) · PubMed · Cited by 127
Stutz, F., & Rosbash, M. (1998) · Genes & Development · doi:10.1101/gad.12.21.3303 · Cited by 126
Krieg, M., Marti, H. H., & Plate, K. H. (1998) · Blood · doi:10.1182/blood.v92.9.3388 · Cited by 126
Expression pattern of the von Hippel-Lindau protein in human tissues.
Los, M., Jansen, G. H., Kaelin, W. G., Lips, C. J. M., Blijham, G. H., & Voest, E. E. (1996) · PubMed · Cited by 125
Self-citationBaba, M., Hirai, S., Yamada‐Okabe, H., Hamada, K., Tabuchi, H., Kobayashi, K., Kondo, K., Yoshida, M., Yamashita, A., Kishida, T., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206373 · Cited by 122
Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues
Corless, C. L., Kibel, A. S., Iliopoulos, O., & Kaelin, W. G. (1997) · Human Pathology · doi:10.1016/s0046-8177(97)90035-6 · Cited by 121
Self-citationMechanism of von Hippel-Lindau Protein-Mediated Suppression of Nuclear Factor kappa B Activity
An, J., & Rettig, M. B. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.17.7546-7556.2005 · Cited by 118
Interplay between VHL/HIF1α and Wnt/β-catenin pathways during colorectal tumorigenesis
Giles, R. H., Lolkema, M. P., Snijckers, C. M. J. T., Belderbos, M. E., van der Groep, P., Mans, D. A., van Beest, M., van Noort, M., Goldschmeding, R., van Diest, P. J., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1209330 · Cited by 118
The use of dioxygen by HIF prolyl hydroxylase (PHD1)
McNeill, L. A., Hewitson, K. S., Gleadle, J. M., Horsfall, L. E., Oldham, N. J., Maxwell, P. H., Pugh, C. W., Ratcliffe, P. J., & Schofield, C. J. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00219-6 · Cited by 116
Ma, W., Tessarollo, L., Hong, S., Baba, M., Southon, E. A., Back, T. C., Spence, S. E., Lobe, C. G., Sharma, N. D., Maher, G., et al. (2003) · PubMed · Cited by 113
Epididymal cystadenomas in von Hippel-Lindau disease
Choyke, P. L., Glenn, G. M., Wagner, J. P., et al. (1997) · Urology · doi:10.1016/s0090-4295(97)00074-5 · Cited by 113
Girmens, J., Erginay, A., Massin, P., et al. (2003) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(03)00101-6 · Cited by 112
Glavač, D., Neumann, H. P. H., Wittke, C., Jaenig, H., Masek, O., Streicher, T., Pausch, F., Engelhardt, D., Plate, K. H., Höfler, H., et al. (1996) · Human Genetics · doi:10.1007/s004390050206 · Cited by 110
Aminova, L. R., Chavez, J. C., Lee, J.-H., Ryu, H., Kung, A. L., LaManna, J. C., & Ratan, R. R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m409223200 · Cited by 109
Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene.
Chen, F., Kishida, T., Duh, F.-M. C., Renbaum, P., Orcutt, M. L., Schmidt, L. S., & Zbar, B. (1995) · PubMed · Cited by 108
Neumann, H. P. H. (1995) · JAMA · doi:10.1001/jama.1995.03530140061033 · Cited by 107
Davidowitz, E. J., Schoenfeld, A. R., & Burk, R. D. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.3.865-874.2001 · Cited by 106
Growth regulation of human renal carcinoma cells: role of transforming growth factor alpha.
Atlas, I., Mendelsohn, J., Baselga, J. M., Fair, W. R., Masui, H., & Kumar, R. (1992) · PubMed · Cited by 105
Vortmeyer, A. O., Lubensky, I. A., Fogt, F., Linehan, W. M., Khettry, U., & Zhuang, Z. (1997) · Europe PMC (PubMed Central) · Cited by 104
Developmental arrest of angioblastic lineage initiates tumorigenesis in von Hippel-Lindau disease.
Vortmeyer, A. O., Frank, S., Jeong, S. Y., Yuan, K. C., Ikejiri, B. L., Lee, Y. S., Bhowmick, D. A., Lonser, R. R., Smith, R. D., Rodgers, G. P., et al. (2003) · PubMed · Cited by 104
Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis
Richards, F., Schofield, P. N., Fleming, S., & Maher, E. R. (1996) · Human Molecular Genetics · doi:10.1093/hmg/5.5.639 · Cited by 104
Aso, T., Haque, D., Barstead, R. J., Conaway, R., & Conaway, J. W. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00940.x · Cited by 103
Regulation of ubiquitin ligase dynamics by the nucleolus
Mekhail, K., Khacho, M., Carrigan, A., Hache, R. R. J., Gunaratnam, L., & Lee, S. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200506030 · Cited by 102
pVHL Function Is Essential for Endothelial Extracellular Matrix Deposition
Tang, N., Mack, F. A., Haase, V. H., Simon, M. C., & Johnson, R. S. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.7.2519-2530.2006 · Cited by 102
Molecular genetic diagnosis of von Hippel-Lindau disease in familial phaeochromocytoma.
Crossey, P. A., Eng, C., Ginalska-Malinowska, M., Lennard, T. W. J., Wheeler, D., Ponder, B. A. J., & Maher, E. R. (1995) · Journal of Medical Genetics · doi:10.1136/jmg.32.11.885 · Cited by 102
Okuda, H., Hirai, S.-I., Takaki, Y., Kamada, M., Baba, M., Sakai, N., Kishida, T., Kaneko, S., Yao, M., Ohno, S., et al. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1347 · Cited by 100
Lipscomb, E. A., Sarmiere, P. D., & Freeman, R. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008407200 · Cited by 98
Hansen, W. J., Ohh, M., Moslehi, J. J., Kondo, K., Kaelin, W. G., & Welch, W. J. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.6.1947-1960.2002 · Cited by 98
Self-citationNa, X., Duan, H. O., Messing, E. M., Schoen, S. R., Ryan, C. K., di Sant'Agnese, P. A., Golemis, E. A., & Wu, G. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg410 · Cited by 95
Lieubeau, B., Rak, J. W., Jothy, S., Iliopoulos, O., Kaelin, W. G., & Kerbel, R. S. (1998) · PubMed · Cited by 91
Self-citationPolycythemia: Mechanisms and Management
Golde, D. W., HOCKING, W. G., KOEFFLER, H. P., & ADAMSON, J. W. (1981) · Annals of Internal Medicine · doi:10.7326/0003-4819-95-1-71 · Cited by 90
(1947) · JAMA · doi:10.1001/jama.1947.02880020069028 · Cited by 90
Genotype–phenotype correlations in von hippel–lindau disease
Neumann, H. P. H., & Bender, B. (1998) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1998.00336.x · Cited by 89
Expression of Growth Factors and Growth Factor Receptors in Capillary Hemangioblastoma
Böhling, T., Hatva, E., Kujala, M., Claesson, L., Alitalo, K. K., & Haltia, M. (1996) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199605000-00004 · Cited by 89
The VHL protein recruits a novel KRAB‐A domain protein to repress HIF‐1α transcriptional activity
Li, Z., Wang, D., Na, X., Schoen, S. R., Messing, E. M., & Wu, G. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg173 · Cited by 89
Petrides, P. E., Bock, S., Bovens, J., Hofmann, R. W., & Jakse, G. (1990) · PubMed · Cited by 89
Humes, H. D., Beals, T. F., Cieslinski, D. A., Sanchez, I. O., & Page, T. (1991) · PubMed · Cited by 89
Levy, A. P., Levy, N. S., Iliopoulos, O., Jiang, C., Kaelin, W. G., & Goldberg, M. A. (1997) · Kidney International · doi:10.1038/ki.1997.82 · Cited by 88
Self-citationCalzada, M. J., Esteban, M. A., Feijoo‐Cuaresma, M., Castellanos, M. C., Naranjo‐Suarez, S., Temes, E., Méndez, F., Yáñez‐Mó, M., Ohh, M., & Landázuri, M. O. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3236 · Cited by 85
Detailed mapping of germline deletions of the von Hippel—Lindau disease tumour suppressor gene
Richards, F. M., Crossey, P. A., Phipps, M. E., Foster, K., Latif, F., Evans, D. G., Sampson, J. R., Lerman, M. I., Zbar, B., Affara, N. A., et al. (1994) · Human Molecular Genetics · doi:10.1093/hmg/3.4.595 · Cited by 85
Corn, P. G., McDonald, E. R., Herman, J. G., & El‐Deiry, W. S. (2003) · Nature Genetics · doi:10.1038/ng1254 · Cited by 84
Datta, K., Nambudripad, R., Pal, S., Zhou, M., Cohen, H. T., & Mukhopadhyay, D. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m909970199 · Cited by 84
Knauth, K., Bex, C., Jemth, P., & Buchberger, A. (2005) · Oncogene · doi:10.1038/sj.onc.1209062 · Cited by 83
Esteban-Barragán, M. A., Ávila, P., Álvarez-Tejado, M., Gutiérrez, M. D. C., García-Pardo, A., Sánchez‐Madrid, F., & Landázuri, M. O. (2002) · PubMed · Cited by 83
Expression of the SM‐20 Gene Promotes Death in Nerve Growth Factor‐Dependent Sympathetic Neurons
Lipscomb, E. A., Sarmiere, P. D., Crowder, R., & Freeman, R. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0730429.x · Cited by 82
The von Hippel-Lindau Tumor Suppressor Stabilizes Novel Plant Homeodomain Protein Jade-1
Zhou, M. I., Wang, H., Ross, J. J., Kuzmin, I., Xu, C., & Cohen, H. T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205040200 · Cited by 81
Galbán, S., Fan, J., Martindale, J. L., Cheadle, C., Hoffman, B. E., Woods, M. P., Temeles, G. L., Brieger, J., Decker, J., & Gorospe, M. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.7.2316-2328.2003 · Cited by 81
Pathology, genetics and cell biology of hemangioblastomas.
Wizigmann-Voos, S., & Plate, K. H. (1996) · PubMed · Cited by 81
Hara, S., Nakashiro, K., Klosek, S. K., Ishikawa, T., Shintani, S., & Hamakawa, H. (2006) · Oral Oncology · doi:10.1016/j.oraloncology.2005.10.016 · Cited by 79
Hofstra, R. M. W., Stelwagen, T., Stulp, R. P., Jong, D. D., Hulsbeek, M. M. F., Kamsteeg, E.-J., van den Berg, A., Landsvater, R. M., Vermey, A., Molenaar, W. M., et al. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.8.8768845 · Cited by 79
Translation of Ischemic Preconditioning to the Patient
Ratan, R. R., Siddiq, A., Aminova, L. R., Lange, P. S., Langley, B. C., Ayoub, I. A., Gensert, J. M., & Chavez, J. C. (2004) · Stroke · doi:10.1161/01.str.0000143216.85349.9e · Cited by 78
Datta, K., Sundberg, C. J., Karumanchi, S. A., & Mukhopadhyay, D. (2001) · PubMed · Cited by 78
Identification of the promoter of the human von Hippel-Lindau disease tumor suppressor gene.
Kuzmin, I., Duh, F.-M. C., Latif, F., Geil, L., Zbar, B., & Lerman, M. I. (1995) · PubMed · Cited by 77
Antiangiogenic Therapy for von Hippel-Lindau Disease
Madhusudan, S. (2004) · JAMA · doi:10.1001/jama.291.8.943 · Cited by 75
Gorospe, M., Egan, J. M., Zbar, B., Lerman, M. I., Geil, L., Kuzmin, I., & Holbrook, N. J. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1289 · Cited by 74
Bodmer, D., Eleveld, M. J., Ligtenberg, M. J. L., Weterman, M. A. J., Janssen, B. A. P., Smeets, D., de Wit, P. E. J., van den Berg, A., van den Berg, E., Koolen, M. I., et al. (1998) · The American Journal of Human Genetics · doi:10.1086/301888 · Cited by 73
Somatic mosaicism in von Hippel-Lindau disease
Murgia, A., Martella, M., Vinanzi, C., Polli, R., Perilongo, G., & Opocher, G. (2000) · Human Mutation · doi:10.1002/(sici)1098-1004(200001)15:1<114::aid-humu20>3.0.co;2-7 · Cited by 73
Pioli, P. A., & Rigby, W. F. C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105391200 · Cited by 72
Nakamura, E., de Abreu-e-Lima, P. C., Awakura, Y., Inoue, T., Kamoto, T., Ogawa, O., Kotani, H., Manabe, T., Zhang, G., Kondo, K., et al. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.050867 · Cited by 72
Self-citationTse, J. Y. M., Wong, J. H. C., Lo, K. W., Poon, W. S., Huang, D. P., & Ng, H. (1997) · American Journal of Clinical Pathology · doi:10.1093/ajcp/107.4.459 · Cited by 72
Analogues of dealanylalahopcin are inhibitors of human HIF prolyl hydroxylases
Schlemminger, I., Mole, D. R., McNeill, L. A., Dhanda, A., Hewitson, K. S., Tian, Y., Ratcliffe, P. J., Pugh, C. W., & Schofield, C. J. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00149-5 · Cited by 71
Wang, F., Sekine, H., Kikuchi, Y., Takasaki, C., Miura, C., Heiwa, O., Shuin, T., Fujii‐Kuriyama, Y., & Sogawa, K. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00729-5 · Cited by 70
Isolated familial pheochromocytoma as a variant of von Hippel-Lindau disease
Ritter, M. M., Frilling, A., Crossey, P. A., Höppner, W., Maher, E. R., Mulligan, L. M., Ponder, B. A. J., & Engelhardt, D. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.3.8772572 · Cited by 70
Chen, F., Slife, L., Kishida, T., Mulvihill, J. J., Tisherman, S. E., & Zbar, B. (1996) · Journal of Medical Genetics · doi:10.1136/jmg.33.8.716 · Cited by 70
Role of Exon 2-encoded β-Domain of the von Hippel-Lindau Tumor Suppressor Protein
Bonicalzi, M.-E., Groulx, I., de Paulsen, N., & Lee, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008295200 · Cited by 68
Kamura, T., Brower, C. S., Conaway, R., & Conaway, J. W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203344200 · Cited by 68
Lager, D. J., Slagel, D. D., & Palechek, P. L. (1994) · PubMed · Cited by 68
Zhou, M. I., Wang, H., Foy, R. L., Ross, J. J., & Cohen, H. T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-0884 · Cited by 66
Gao, J., Naglich, J. G., Laidlaw, J., Whaley, J. M., Seizinger, B. R., & Kley, N. (1995) · PubMed · Cited by 65
Renal lesions and pheochromocytoma in von Hippel-Lindau disease.
Richard, S., Chauveau, D., Chrétien, Y., et al. (1994) · PubMed · Cited by 63
Hayashi, M., Sakata, M., Takeda, T., Tahara, M., Yamamoto, T., Okamoto, Y., Minekawa, R., Isobe, A., Ohmichi, M., Tasaka, K., et al. (2005) · Endocrinology · doi:10.1210/en.2005-0416 · Cited by 62
Tumor Suppression by the von Hippel-Lindau Protein Requires Phosphorylation of the Acidic Domain
Lolkema, M. P., Gervais, M. L., Snijckers, C. M. J. T., Hill, R. P., Giles, R. H., Voest, E. E., & Ohh, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503220200 · Cited by 61
Altered expression of transforming growth factor-alpha in hereditary rat renal cell carcinoma.
Walker, C. L., Everitt, J. I., Freed, J. J., Knudson, A. G., & Whiteley, L. O. (1991) · PubMed · Cited by 60
Lee, Y., Vortmeyer, A. O., Lubensky, I. A., Vogel, T. W. A., Ikejiri, B. L., Ferlicot, S., Benoît, G., Giraud, S., Oldfield, E. H., Linehan, W. M., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.1059.11.3 · Cited by 60
The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis
Schoenfeld, A. R., Parris, T., Eisenberger, A. B., Davidowitz, E. J., Leon, M. D., Talasazan, F., Devarajan, P., & Burk, R. D. (2000) · Oncogene · doi:10.1038/sj.onc.1203985 · Cited by 59
Cryptic von Hippel-Lindau disease: germline mutations in patients with haemangioblastoma only
Hes, F. J., McKee, S., TAPHOORN, M. J. B., Rehal, P., van der Luijt, R. B., McMahon, R., van der Smagt, J. J., Dow, D., Zewald, R. A., Whittaker, J., et al. (2000) · Journal of Medical Genetics · doi:10.1136/jmg.37.12.939 · Cited by 58
An Important von Hippel-Lindau Tumor Suppressor Domain Mediates Sp1-Binding and Self-Association
Cohen, H. T., Zhou, M., Welsh, A. M., Zarghamee, S., Scholz, H., Mukhopadhyay, D., Kishida, T., Zbar, B., Knebelmann, B., & Sukhatme, V. P. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1767 · Cited by 57
von Hippel-Lindau protein promotes the assembly of actin and vinculin and inhibits cell motility.
Kamada, M., Suzuki, K., Kato, Y., Okuda, H., & Shuin, T. (2001) · PubMed · Cited by 56
Kim, M., Katayose, Y., Li, Q., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9839 · Cited by 56
Reifenberger, G., REIFENBERGER, J., Bilzer, T., Wechsler, W., & Collins, V. P. (1995) · Europe PMC (PubMed Central) · Cited by 53
Familial pheochromocytoma associated with a novel mutation in the von Hippel-Lindau gene
Gross, D. J., Avishai, N., Meiner, V., Filon, D., Zbar, B., & Abeliovich, D. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550742 · Cited by 52
Kessler, P., Vasavada, S. P., Rackley, R. R., Stackhouse, T. M., Duh, F.-M. C., Latif, F., Lerman, M. I., Zbar, B., & Williams, B. R. G. (1995) · Molecular Medicine · doi:10.1007/bf03401583 · Cited by 51
Straub, J. A., Lipscomb, E. A., Yoshida, E. S., & Freeman, R. S. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01688.x · Cited by 49
Baba, M., Hirai, S.-I., Kawakami, S., Kishida, T., Sakai, N., Kaneko, S., Yao, M., Shuin, T., Kubota, Y., Hosaka, M., et al. (2001) · Oncogene · doi:10.1038/sj.onc.1204397 · Cited by 49
Frequent Overexpression of Vascular Endothelial Growth Factor Gene in Human Renal Cell Carcinoma.
Sato, K., Terada, K., Sugiyama, T., et al. (1994) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.173.355 · Cited by 49
Datta, K., Mondal, S., Sinha, S., Li, J., Wang, E., Knebelmann, B., Karumanchi, S. A., & Mukhopadhyay, D. (2005) · Oncogene · doi:10.1038/sj.onc.1208912 · Cited by 49
Richard, S., Croisille, L., Yvart, J., Casadeval, N., Eschwège, P., Aghakhani, N., David, P., Gaudric, A., Scigalla, P., & Hermine, O. (2002) · Blood · doi:10.1182/blood.v99.10.3851 · Cited by 48
Zhuang, Z., Emmert‐Buck, M. R., Roth, M. J., Gnarra, J. R., Linehan, W. M., Liotta, L. A., & Lubensky, I. A. (1996) · Human Pathology · doi:10.1016/s0046-8177(96)90368-8 · Cited by 48
The von Hippel-Lindau tumor suppressor targets to mitochondria.
Shiao, Y., Resau, J. H., Nagashima, K., Anderson, L. M., & Ramakrishna, G. (2000) · PubMed · Cited by 48
Renbaum, P., Duh, F.-M. C., Latif, F., Zbar, B., Lerman, M. I., & Kuzmin, I. (1996) · Human Genetics · doi:10.1007/s004390050281 · Cited by 47
Subcellular localization of the von Hippel-Lindau disease gene product is cell cycle-dependent
Ye, Y., Vasavada, S. P., Kuzmin, I., Stackhouse, T. M., Zbar, B., & Williams, B. R. G. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980925)78:1<62::aid-ijc11>3.0.co;2-7 · Cited by 45
The Elongin BC complex and the von Hippel–Lindau tumor suppressor protein
Conaway, J. W., Kamura, T., & Conaway, R. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00035-8 · Cited by 45
Chan, C., Chew, E. Y., Shen, D., Hackett, J., & Zhuang, Z. (2005) · PubMed · Cited by 43
Groulx, I., Bonicalzi, M.-E., & Lee, S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.12.8991 · Cited by 43
CALDWELL, M. C., Hough, C. D., Fürer-Galbán, S., Linehan, W. M., Morin, P. J., & Gorospe, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205140 · Cited by 41
The Molecular Basis of Von Hippel-Lindau Disease
Iliopoulos, O., & Kaelin, W. G. (1997) · Molecular Medicine · doi:10.1007/bf03401807 · Cited by 40
Self-citationSchoenfeld, A. R., Davidowitz, E. J., & Burk, R. D. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(20010215)91:4<457::aid-ijc1072>3.0.co;2-p · Cited by 40
SM-20 is a novel 40-kd protein whose expression in the arterial wall is restricted to smooth muscle.
Sd, W., Tsao, L., Me, L., Fallon, J. T., & Mb, T. (1996) · PubMed · Cited by 39
Somatic mutations of von Hippel‐Lindau (VHL) tumor‐suppressor gene in european kidney cancers
Bailly, M., Bain, C., Favrot, M., & Öztürk, M. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910630510 · Cited by 38
Moschella, M. C., Menzies, K. E., Tsao, L., Lieb, M., Kohtz, J. D., Kohtz, D. S., & Taubman, M. B. (1999) · Europe PMC (PubMed Central) · Cited by 27
Takagi, Y., Conaway, R. C., & Conaway, J. W. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.41.25562 · Cited by 21
He, Z., Liu, S., Guo, M. Z., Mao, J., & Hughson, M. D. (2004) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2003.11.001 · Cited by 19
The Elongin B Ubiquitin Homology Domain
Brower, C. S., Shilatifard, A., Mather, T., Kamura, T., Takagi, Y., Haque, D., Treharne, A., Foundling, S. I., Conaway, J. W., & Conaway, R. C. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.19.13629 · Cited by 18
Chat in the trophic web: NGF activates Ret by inter-RTK signaling.
Dechant, G. (2002) · Neuron · doi:10.1016/s0896-6273(02)00564-0 · Cited by 17
CHANGES IN Bcl-2 AND p53 EXPRESSION IN RECURRENT B-CELL LYMPHOMAS
Ilyas, M., KENDALL, M., Jalal, H., Linton, C. J., & ROONEY, N. (1996) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199611)180:3<271::aid-path664>3.0.co;2-2 · Cited by 6
Cited by
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.
Kaelin, W. G., & Ratcliffe, P. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.009 · Cited by 3,251
Self-citationHsieh, J. J., Purdue, M. P., Signoretti, S., Swanton, C., Albiges, L., Schmidinger, M., Heng, D. Y., Larkin, J., & Ficarra, V. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.9 · Cited by 2,426
Eltzschig, H. K., & Carmeliet, P. (2011) · New England Journal of Medicine · doi:10.1056/nejmra0910283 · Cited by 2,061
Epidemiology and risk factors for kidney cancer
Chow, W.-H., Dong, L. M., & Devesa, S. S. (2010) · Nature Reviews Urology · doi:10.1038/nrurol.2010.46 · Cited by 1,384
Metadata
- Authors
- Kaelin, W. G.
- Venue
- Annual Review of Pathology: Mechanisms of Disease
- Publisher
- Annual Reviews
- Published
- 2007-02-01
- Volume
- 2
- Issue
- 1
- Pages
- 145-173
- ISSN
- 1553-4006 (ISSN-L)
- 1553-4014
- OpenAlex
- W2614257677
- Cited by
- 336
- References
- 326
- FWCI
- 1.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.